Font Size Smaller Font Size
Larger Font Size
Latest Press Releases
-
April 12, 2019
Celgene Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
-
April 5, 2019
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
-
March 29, 2019
Celgene Settles U.S. REVLIMID® Patent Litigation with Alvogen
-
March 29, 2019
Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma
-
March 25, 2019
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
-
March 12, 2019
Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer
-
March 11, 2019
Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
-
March 5, 2019
U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis
-
February 26, 2019
Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia
-
January 31, 2019
Celgene Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
-
January 7, 2019
Celgene Corporation Announces 2019 Financial Guidance and Key Milestones
-
January 3, 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
-
December 18, 2018
Celgene Corporation to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
December 17, 2018
Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients
-
December 3, 2018
Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 EVOLVE Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018
-
December 2, 2018
Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R²) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018
-
December 2, 2018
bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
-
December 3, 2018
Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018
-
December 3, 2018
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session
-
December 2, 2018
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
-
November 28, 2018
Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma
-
November 15, 2018
Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis
-
November 3, 2018
Celgene Corporation to Webcast at Upcoming Investor Events
-
November 2, 2018
Results from More Than 100 Abstracts Highlighting Celgene Pipeline Compounds and Therapies to Be Presented at the American Society of Hematology Annual Meeting (ASH)
-
October 25, 2018
Celgene Reports Third Quarter 2018 Operating and Financial Results
-
October 24, 2018
TV Host and Fashion Journalist Louise Roe Shares Her Personal Story With Plaque Psoriasis as Part of INSIDE PERSPECTIVE Campaign
-
October 23, 2018
REVLIMID® (lenalidomide) Demonstrated a Significant Improvement in Progression-Free Survival (PFS) Compared with Observation in a Randomized Study in Patients with Smoldering Multiple Myeloma
-
October 22, 2018
Celgene Corporation Announces Appointment of Dr. Alise Reicin to President, Global Clinical Development
-
October 22, 2018
First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018
-
October 11, 2018
Survey Results Presented at ECTRIMS Reveal People with Multiple Sclerosis Want More Information on Brain Atrophy
-
October 10, 2018
New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018
-
October 8, 2018
Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint
-
October 1, 2018
Celgene Corporation to Announce Third Quarter 2018 Results on October 25, 2018
-
September 12, 2018
OTEZLA® (Apremilast) Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
-
August 23, 2018
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
July 26, 2018
Celgene Reports Second Quarter 2018 Operating and Financial Results
-
July 23, 2018
Celgene Announces Phase III ‘AUGMENT' Study of REVLIMID® in Combination with Rituximab (R²) for the Treatment of Patients with Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint
-
July 10, 2018
Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study
-
July 9, 2018
Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE' Study in Adults with Transfusion-Dependent Beta-Thalassemia
-
July 2, 2018
Celgene Corporation to Announce Second Quarter 2018 Results on July 26, 2018
-
June 28, 2018
Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST' Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes
-
June 19, 2018
Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vice President and General Counsel Following the Departure of Gerald F. Masoudi
-
June 3, 2018
Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel (JCAR017) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO
-
June 3, 2018
Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R²) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018
-
June 1, 2018
Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
-
June 1, 2018
Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma
-
May 31, 2018
Celgene Corporation Announces Hiring of David V. Elkins as Executive Vice President, Chief Financial Officer and Appointment of Peter N. Kellogg to Executive Vice President, Chief Corporate Strategy Officer
-
May 24, 2018
Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program
-
May 22, 2018
Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018
-
May 16, 2018
Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions
-
May 14, 2018
Celgene Corporation to Webcast at Upcoming Investor Conferences and Events
-
May 4, 2018
Celgene Reports First Quarter 2018 Operating and Financial Results
-
April 30, 2018
Celgene Corporation Announces Appointment of Jennifer Dudinak to Senior Vice President of Global Regulatory Affairs
-
April 24, 2018
New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting
-
April 19, 2018
Celgene Corporation Announces Changes to Its Board of Directors
-
April 17, 2018
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
April 9, 2018
Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018
-
April 2, 2018
Celgene Corporation Announces Departure of President and Chief Operating Officer Scott A. Smith
-
March 28, 2018
bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States
-
March 6, 2018
Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
-
March 5, 2018
Celgene Announces Expiration of Cash Tender Offer for Shares of Juno Therapeutics, Inc.
-
February 27, 2018
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
February 27, 2018
Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis
-
February 21, 2018
Celgene Receives Antitrust Clearance for Juno Acquisition
-
February 17, 2018
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet's Disease with Oral Ulcers
-
February 15, 2018
OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
-
February 15, 2018
Celgene Corporation Elects John Weiland to Its Board of Directors
-
February 14, 2018
Celgene Announces Additional $5 Billion Share Repurchase Authorization
-
February 9, 2018
Celgene Prices $4.5 Billion of Senior Unsecured Notes
-
February 8, 2018
Celgene Announces Offering of Senior Unsecured Notes
-
February 6, 2018
Celgene Corporation Announces Positive Results from the Pivotal Phase III ‘OPTIMISMM' Study of POMALYST/IMNOVID® for the Treatment of Relapsed or Refractory Multiple Myeloma
-
February 2, 2018
Celgene Corporation Commences Tender Offer for Juno Therapeutics, Inc.
-
February 1, 2018
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
January 29, 2018
Celgene Announces Retirement of Executive Chairman Bob Hugin and Appointment of CEO Mark Alles as Chairman of the Board of Directors
-
January 25, 2018
Celgene Reports Fourth Quarter and Full-Year 2017 Operating and Financial Results
-
January 22, 2018
Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
-
January 19, 2018
Investigational Data Presented at ASCO GI Evaluate ABRAXANE® Regimen for Patients with Locally Advanced Pancreatic Cancer
-
January 8, 2018
Celgene Corporation Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance
-
January 7, 2018
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies
-
January 3, 2018
Celgene Corporation to Announce Fourth Quarter and Full-Year 2017 Results on January 25, 2018
-
January 2, 2018
Celgene Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference
-
December 21, 2017
Celgene and LYSARC Provide Update on Phase III ‘RELEVANCE' Study of REVLIMID® in Combination with Rituximab (R²) for the Treatment of Previously Untreated Patients with Follicular Lymphoma
-
December 11, 2017
Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
-
December 10, 2017
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
-
December 7, 2017
Long-Term Efficacy Data from the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated with ABRAXANE® Vs. Solvent-Based Paclitaxel to Be Reported
-
December 5, 2017
Celgene Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Capacity Building in Resource-Constrained Countries
-
November 21, 2017
Celgene Corporation to Webcast an Analyst and Investor Event from the American Society of Hematology Meeting in December
-
November 21, 2017
Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American Society of Hematology Annual Meeting (ASH)
-
November 16, 2017
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma
-
November 1, 2017
Celgene Prices $3 Billion of Senior Unsecured Notes
-
October 31, 2017
Celgene Announces Offering of Senior Unsecured Notes
-
October 28, 2017
Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
-
October 27, 2017
Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
-
October 27, 2017
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
October 26, 2017
Celgene Reports Third Quarter 2017 Operating and Financial Results
-
October 19, 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
-
October 19, 2017
Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
-
October 16, 2017
Results from Phase 2 Studies of Oral Ozanimod in Crohn's Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017
-
October 2, 2017
Celgene Corporation to Announce Third Quarter 2017 Results on October 26, 2017; Will Host an Investor Webcast Event from the MSParis2017-7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017
-
September 8, 2017
Data Presented at ESMO 2017 Further Evaluate Role of ABRAXANE® for Patients with Historically Challenging Cancers
-
September 7, 2017
Celgene Provides Update on the Fusion™ Clinical Program
-
August 24, 2017
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
August 1, 2017
FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation
-
July 28, 2017
Celgene Corporation to Webcast at Upcoming Investor Conference
-
July 27, 2017
Celgene Reports Second Quarter 2017 Operating and Financial Results
-
July 25, 2017
Celgene Corporation Announces Settlement of Civil Litigation
-
July 6, 2017
Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers
-
July 5, 2017
Celgene Corporation to Announce Second Quarter 2017 Results on July 27, 2017
-
June 22, 2017
Celebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgene's SHOW MORE OF YOU Campaign
-
June 19, 2017
Celgene Announces Clinical Data Evaluating Broad Range of Blood Cancers to Be Presented at EHA 2017
-
June 17, 2017
Updated Data from Phase IIIb MAGNIFY Study of REVLIMID (lenalidomide) and Rituximab Combination (R2) Show Clinical Activity and Responses in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
-
June 14, 2017
Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus
-
June 6, 2017
Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation
-
June 5, 2017
REVLIMID® (lenalidomide) AND POMALYST®/IMNOVID® (pomalidomide) REMAIN FOCUS OF COMBINATION THERAPIES IN MULTIPLE MYELOMA AT ASCO
-
June 5, 2017
bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
-
June 1, 2017
Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia
-
May 22, 2017
Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
-
May 17, 2017
Broad Range of Clinical Data Evaluating Celgene Therapies to Be Presented at American Society of Clinical Oncology (ASCO)
-
May 6, 2017
Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes
-
May 3, 2017
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
April 27, 2017
Celgene Reports First Quarter 2017 Operating and Financial Results
-
April 3, 2017
Celgene Notified of ANDA Filing for POMALYST®
-
April 3, 2017
Celgene Corporation to Announce First Quarter 2017 Results on April 27, 2017
-
March 5, 2017
Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy
-
March 3, 2017
Celgene to Present New Data from Clinical Trials on Oral OTEZLA® (apremilast) at American Academy of Dermatology Congress
-
March 1, 2017
FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation
-
February 27, 2017
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
February 24, 2017
REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation
-
February 23, 2017
Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer
-
February 22, 2017
FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)
-
February 17, 2017
Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis
-
February 3, 2017
Celgene Corporation to Webcast at Upcoming Investor Conference
-
January 27, 2017
Celgene Receives Positive CHMP Opinion to Expand REVLIMID® (Lenalidomide) Indication as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma (MM) after Autologous Stem Cell Transplantation
-
January 26, 2017
Celgene Reports Fourth Quarter and Full-Year 2016 Operating and Financial Results
-
January 26, 2017
Celgene to Acquire Delinia, Inc.
-
January 9, 2017
Celgene Corporation Announces Preliminary 2016 Unaudited Results and 2017 Financial Guidance
-
January 4, 2017
Celgene Corporation to Announce Fourth Quarter and Full-Year 2016 Results on January 26, 2017
-
January 3, 2017
Celgene Corporation to Present at the 35th Annual J.P. Morgan Healthcare Conference
-
December 22, 2016
Oral OTEZLA®▼ (Apremilast) Receives Positive Nice Recommendation for Adults with Psoriatic Arthritis
-
December 20, 2016
Juno Therapeutics' and Celgene Corporation's Investigational Drug JCAR017 Granted Breakthrough Therapy Designation from FDA and Priority Medicines Eligibility from EMA for Relapsed/Refractory Diffuse Large B-cell Lymphoma
-
December 20, 2016
Oral PDE-4 Inhibitor, OTEZLA®, Approved for the Treatment of Plaque Psoriasis and Psoriatic Arthritis in Japan
-
December 7, 2016
tnAcity Data Presented at SABCS Evaluates the Investigational Use of ABRAXANE® as First-Line Treatment of Metastatic Triple Negative Breast Cancer
-
December 6, 2016
Phase III Studies Present Additional Evidence for REVLIMID® (lenalidomide) as Maintenance Therapy in Multiple Myeloma
-
December 6, 2016
ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations
-
December 5, 2016
Combined Analysis of Oral Epigenetic Therapy, CC-486, Demonstrated Hematologic Responses in Patients Who Received Prior Epigenetic Hypo-Methylating Agents (HMA)
-
December 3, 2016
Celgene Corporation, Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project
-
November 22, 2016
Nearly 350 Abstracts Evaluating Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting (ASH)
-
November 21, 2016
Celgene Corporation to Webcast an Analyst and Investor Event from the American Society of Hematology Meeting in December
-
November 14, 2016
Data on Early Onset of Efficacy for Oral OTEZLA® (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology
-
November 1, 2016
Celgene and IBM Watson Health Forge Collaboration Designed to Transform Patient Safety Monitoring
-
October 27, 2016
Celgene Reports Third Quarter 2016 Operating and Financial Results
-
October 24, 2016
Celgene Corporation to Webcast at Upcoming Investor Conferences in November
-
October 20, 2016
Oral OTEZLA® ▼ (Apremilast) Receives Positive Nice Recommendation for Adults with Chronic Plaque Psoriasis
-
October 18, 2016
Celgene Corporation and Sage Bionetworks Announce Technology Collaboration to Develop Observational Study Using the Apple ResearchKit Framework
-
October 17, 2016
Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG
-
October 16, 2016
Oral GED-0301 Phase 1b Results Show Clinical Remission and Endoscopic Response at Week 12 in Patients with Active Crohn's Disease
-
October 13, 2016
Celgene to Present New Data on Investigational Compounds at UEGW and ACG Congresses
-
October 12, 2016
Celgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML
-
October 7, 2016
Data Presented at ESMO 2016 Adds to Understanding of Abraxane® as a Therapy for Patients with Historically Challenging Solid Tumors
-
October 4, 2016
Celgene Announces Acceptance of Late Breaking GED-0301 CD-001 Abstract at the United European Gastroenterology Week (UEGW) Meeting
-
October 3, 2016
Celgene Corporation to Announce Third Quarter 2016 Results on October 27, 2016
-
September 28, 2016
Oral OTEZLA® (apremilast) Long-Term Safety Data Presented at EADV Congress in Both Psoriasis and Psoriatic Arthritis
-
September 16, 2016
Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS
-
September 13, 2016
First-Ever Psoriatic Arthritis Awareness Day Aims to Educate on Importance of Early Diagnosis and Treatment
-
September 12, 2016
Celgene Announces Interim Topline Data from Trial of Investigational Oral GED-0301 in Patients with Active Crohn's Disease
-
August 29, 2016
Celgene Corporation to Webcast at Upcoming Investor Conferences and R&D Deep Dive in September
-
August 17, 2016
Olympic Swimmer and Author Dara Torres Teams Up With Celgene to Launch SHOW MORE OF YOU Psoriasis Campaign
-
July 28, 2016
Celgene Reports Second Quarter 2016 Operating and Financial Results
-
July 25, 2016
Celgene and LYSARC Provide Update on the Phase III ‘REMARC' Study of REVLIMID® Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy
-
July 15, 2016
REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
-
July 1, 2016
Celgene Corporation to Announce Second Quarter 2016 Results on July 28, 2016
-
June 22, 2016
Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene
-
June 15, 2016
Celgene Announces Additional $3 Billion Share Repurchase Authorization
-
June 10, 2016
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
-
June 9, 2016
Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
-
June 7, 2016
Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
-
June 4, 2016
Data Presented at ASCO 2016 Builds upon Foundation of Abraxane® Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
-
June 3, 2016
Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID® Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma
-
May 20, 2016
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
May 18, 2016
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2016
-
May 17, 2016
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
-
May 17, 2016
Celgene Launches Fictional Film, Millefeuille, to Shed New Light on Complex Psoriasis Challenges
-
April 28, 2016
Celgene Reports First Quarter 2016 Operating and Financial Results
-
April 27, 2016
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
April 1, 2016
Celgene Corporation to Announce First Quarter 2016 Results on April 28, 2016
-
March 18, 2016
Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial
-
March 7, 2016
Celgene Notified of ANDA Filing for ABRAXANE®
-
March 7, 2016
Oral OTEZLA® (Apremilast) Long-Term Safety Data Presented at American Academy of Dermatology Congress
-
March 4, 2016
Oral OTEZLA® (apremilast) Data from Open-Label Phase of ESTEEM and LIBERATE™ Trials to Be Presented at American Academy of Dermatology Congress
-
February 29, 2016
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
February 27, 2016
Two Quality of Life (QoL) Interim Analyses Presented at ASCO Quality Care Symposium Represent First Results from ABOUND ABRAXANE® Lung Cancer Program
-
February 18, 2016
Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS
-
February 11, 2016
Celgene Corporation Elects Mark Alles and Jacqualyn Fouse PhD to its Board of Directors
-
February 1, 2016
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
January 28, 2016
Celgene Reports Fourth Quarter and Full Year 2015 Operating and Financial Results
-
January 22, 2016
Data Presented at ASCO GI Highlight the Feasibility of Second-Line Treatment in Patients with Metastatic Pancreatic Cancer Who Have Received First-Line Abraxane Plus Gemcitabine
-
January 22, 2016
Investigational Combinations Using an ABRAXANE and Gemcitabine Foundation Lead ASCO GI Pancreatic Cancer Research
-
January 22, 2016
Be Counted! Campaign Brings Together the Psoriatic Arthritis Community to Increase Understanding of This Chronic, Autoimmune Disease
-
January 11, 2016
Organizational Changes Strengthen Leadership Team and Position Celgene for Long-Term Growth
-
January 11, 2016
Celgene Corporation Announces 2016 Financial Outlook and Preliminary 2015 Results
-
January 5, 2016
Celgene Corporation to Announce Fourth Quarter and Full-Year 2015 Results on January 28, 2016
-
January 4, 2016
Celgene Corporation to Present at the 34th Annual J.P. Morgan Healthcare Conference
-
December 22, 2015
Celgene Settles REVLIMID® Patent Litigation
-
December 21, 2015
Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
-
December 9, 2015
Abstracts at San Antonio Breast Cancer Symposium Highlight ABRAXANE® as a Potential Backbone Therapy in Neoadjuvant and Triple-Negative-Breast Cancer
-
December 7, 2015
Celgene in Collaboration with Astrazeneca Announce Initiation of Fusion Clinical Development Program in Immuno-Oncology
-
December 6, 2015
IMiD® Combination Therapies Form Backbone of Multiple Myeloma Research at ASH
-
December 5, 2015
Study of Bortezomib Added to Revlimid® and Dexamethasone Backbone Therapy Presented at ASH
-
November 5, 2015
Celgene Reports Third Quarter 2015 Operating and Financial Results
-
October 30, 2015
Celgene's VIDAZA® (Azacitidine For Injection) Approved By The European Commission As New Treatment For Elderly Patients With Acute Myeloid Leukaemia
-
October 27, 2015
Celgene Corporation to Webcast at Upcoming Investor Conference and Medical Congress
-
October 26, 2015
Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week
-
October 19, 2015
Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session
-
October 16, 2015
Celgene Corporation Elects Julia A. Haller, M.D., to Its Board of Directors
-
October 12, 2015
One Year Data from Phase III Study Evaluating Oral OTEZLA® (apremilast) or Injectable etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at EADV
-
October 9, 2015
Celgene Announces New Data for OTEZLA® (Apremilast) Will Be Presented at European Academy of Dermatology and Venereology Congress
-
October 1, 2015
Celgene Corporation to Announce Third Quarter 2015 Results on November 5, 2015
-
September 25, 2015
Celgene's VIDAZA® (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
-
August 27, 2015
Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases
-
August 26, 2015
Celgene Corporation to Webcast Upcoming Investor Conferences in September
-
August 25, 2015
Celgene Announces Expiration of Cash Tender Offer for Shares of Receptos, Inc.
-
August 11, 2015
Celgene Receives Antitrust Clearance for Receptos Acquisition
-
August 4, 2015
Celgene Prices $8 Billion of Senior Unsecured Notes
-
August 3, 2015
Celgene Announces Offering of Senior Unsecured Notes
-
July 28, 2015
Celgene Corporation Commences Tender Offer for Receptos, Inc.
-
July 23, 2015
Celgene Reports Second Quarter 2015 Operating and Financial Results
-
July 14, 2015
Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases
-
July 6, 2015
Celgene Corporation to Announce Second Quarter 2015 Results on July 23, 2015
-
June 29, 2015
Celgene and Juno Announce Ten-Year Collaboration to Advance Potentially Groundbreaking Immunotherapies for Patients with Cancer and Autoimmune Diseases
-
June 17, 2015
Celgene Announces Additional $4 Billion Share Repurchase Authorization
-
June 13, 2015
Results from Analyses of Revlimid® MCL-002 (SPRINT) Study Presented at EHA
-
June 12, 2015
Updated Results from MM-020/IFM 07-01 (First) Study of REVLIMID® Presented at European Hematology Annual Congress
-
June 9, 2015
Oral Presentation Evaluating Pooled Data on OTEZLA® (apremilast) for Long-Term Improvements in Enthesitis and Dactylitis to Be Presented at EULAR
-
June 3, 2015
Celgene Announces New Data to be Presented at European League Against Rheumatism Annual Congress
-
May 28, 2015
Celgene Corporation to Webcast at Upcoming Investor Conferences in June
-
May 19, 2015
Analysis of Phase II Data for Celgene's Investigational Oral GED-0301 in Patients with Active Crohn's Disease Presented at Digestive Disease Week
-
May 13, 2015
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2015
-
May 1, 2015
Analysis of REVLIMID® (Lenalidomide) in Patients with Non-Del-5Q MDS Demonstrated Improved Health Related Quality of Life Measures
-
April 30, 2015
Celgene Reports First Quarter 2015 Operating and Financial Results
-
April 27, 2015
Celgene to Acquire Quanticel Pharmaceuticals
-
April 24, 2015
Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop PD-L1 Inhibitor Program for Patients with Serious Blood Cancers
-
April 23, 2015
POMALYST® (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA
-
April 23, 2015
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Meetings in May
-
April 15, 2015
Phase II Data for Apremilast in Behçet's Disease Published in The New England Journal of Medicine
-
April 15, 2015
Celgene Corporation Elects Mr. Michael W. Bonney to Its Board of Directors
-
April 1, 2015
Celgene Corporation to Announce First Quarter 2015 Results on April 30, 2015
-
April 1, 2015
Celgene Corporation Announces the Appointment of Gerald F. Masoudi as Executive Vice President, General Counsel and Corporate Secretary Following the Retirement of Lawrence V. Stein
-
March 20, 2015
Oral OTEZLA® (apremilast) Long-Term Safety and Efficacy Data in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD
-
March 20, 2015
Positive Results from Phase III Study Evaluating Oral OTEZLA® (Apremilast) or Injectable Etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD
-
March 18, 2015
Phase II Data for Celgene's Investigational Oral GED-0301 for Patients with Active Crohn's Disease Published in New England Journal of Medicine
-
March 2, 2015
ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
-
February 20, 2015
REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
-
February 19, 2015
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
February 18, 2015
FDA Expands Indication for REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma
-
February 10, 2015
Celgene Announces Positive Recommendation by Scottish Medicines Consortium (SMC) for ABRAXANE® (Nab-Paclitaxel) in combination with Gemcitabine1 for Patients with Metastatic Pancreatic Cancer
-
January 29, 2015
Celgene Reports Fourth Quarter and Full Year 2014 Operating and Financial Results
-
January 27, 2015
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
January 23, 2015
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
-
January 16, 2015
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis
-
January 12, 2015
Celgene Corporation Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Results
-
January 6, 2015
Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference
-
December 19, 2014
Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant
-
December 9, 2014
Combination of ISTODAX® (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients with Peripheral T-Cell Lymphoma
-
December 9, 2014
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition
-
December 9, 2014
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH
-
December 9, 2014
Results from Phase IIIb Study of POMALYST®/IMNOVID® (pomalidomide) Plus Low-Dose dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Presented at ASH
-
December 9, 2014
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators' Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
-
December 9, 2014
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH
-
December 8, 2014
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH
-
December 8, 2014
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01) Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH
-
December 1, 2014
Celgene Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Corporation
-
November 21, 2014
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis
-
November 18, 2014
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis
-
November 13, 2014
Global Survey Finds That Pancreatic Cancer, a Leading Cause of Cancer Deaths, is Virtually Unknown by Many in Europe and US
-
November 6, 2014
Data from More Than 160 Abstracts Highlighting Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting (ASH)
-
October 31, 2014
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress
-
October 23, 2014
Celgene Reports Third Quarter 2014 Operating and Financial Results
-
October 20, 2014
Phase II Data in Crohn's Disease for Celgene's Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014
-
October 10, 2014
Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis
-
October 10, 2014
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis
-
October 7, 2014
Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis And Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress
-
October 1, 2014
Celgene Corporation to Announce Third Quarter 2014 Results on October 23, 2014
-
September 23, 2014
Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis
-
September 4, 2014
Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine
-
August 21, 2014
Celgene Corporation to Present at Investor Conferences in September
-
August 20, 2014
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen
-
August 19, 2014
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate
-
July 24, 2014
Celgene Reports Second Quarter 2014 Operating and Financial Results
-
July 9, 2014
Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis
-
July 1, 2014
Celgene Corporation to Announce Second Quarter 2014 Results on July 24, 2014
-
June 26, 2014
Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake
-
June 19, 2014
Celgene Stockholders Approve Two-for-One Stock Split
-
June 14, 2014
Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in Beta-Thalassemia
-
June 11, 2014
Oral OTEZLA® (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Naïve Patients with Active Psoriatic Arthritis
-
June 11, 2014
Oral OTEZLA® (Apremilast) Showed Long-Term Clinical Benefits in Patients with Active Psoriatic Arthritis
-
June 1, 2014
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014
-
May 20, 2014
Celgene Corporation to Present at Investor Conferences in June
-
May 14, 2014
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2014
-
May 6, 2014
Celgene Announces Offering of Senior Unsecured Notes
-
April 1, 2014
Celgene Corporation to Announce First Quarter 2014 Results on April 24, 2014
-
March 23, 2014
Oral OTEZLA® (apremilast) Demonstrated Clinically Meaningful and Sustained Improvements in Skin, Nail and Scalp of Adult Patients with Moderate to Severe Plaque Psoriasis
-
March 21, 2014
OTEZLA® (apremilast) - First Oral Therapy Approved by the U.S. Food and Drug Administration for the Treatment of Adults with Active Psoriatic Arthritis
-
March 20, 2014
First-of-Its-Kind Multinational Survey Confirms Psoriasis and Psoriatic Arthritis Patients Are Frequently Undertreated or Not Treated at All
-
March 19, 2014
Celgene Reiterates Commitment to Improving Pancreatic Cancer Care in Europe, Through Significant Research and Patient Support Initiatives
-
February 13, 2014
Celgene Corporation Board of Directors Recommends to Our Stockholders a Two-for-One Stock Split
-
January 22, 2014
Celgene Corporation to Announce Fourth Quarter and Full Year 2013 Results on January 30, 2014
-
January 13, 2014
Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results
-
January 10, 2014
Celgene Corporation to Present 2013 Unaudited Financial Results and Updated Financial Outlook at the 32nd Annual J.P. Morgan Healthcare Conference
-
January 7, 2014
ABRAXANE® Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer
-
January 2, 2014
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference
-
December 10, 2013
Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH
-
December 10, 2013
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST®/IMNOVID® (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH
-
December 9, 2013
REVLIMID® (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response
-
December 7, 2013
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH
-
November 22, 2013
Celgene Receives Positive CHMP Opinion for ABRAXANE® in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer
No results found.